GlassScriptPhysician profile
John M Aversa
NPI 1588830699
$2,356.26
in general payments reported to CMS, 2019-2025
12 companies · $95.88 in 2025
The $95.88 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.88 · 2021: $139 · 2022: $61.01 · 2023: $262 · 2024: $1,754 · 2025: $95.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,425 · Food and Beverage: $398 · Travel and Lodging: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,425.00 |
| Food and Beverage | $397.54 |
| Travel and Lodging | $289.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,725.61 | 2024 | |
| Axonics, INC. | $250.84 | 2021-2023 | Axonics |
| Intuitive Surgical, INC. | $90.41 | 2019-2021 | |
| Csl Behring | $72.61 | 2022-2023 | Kcentra |
| Ethicon US, LLC | $42.70 | 2025 | Harmonic, Echelon; Endopath |
| Solventum Corporation | $30.22 | 2025 | V.A.C.Ulta, Prevena |
| Takeda Pharmaceuticals U.S.A., INC. | $29.50 | 2023 | Gattex |
| Thd America, INC. | $29.01 | 2019-2025 | |
| Qol Medical, LLC | $28.81 | 2024 | Sucraid |
| Integra Lifesciences Corporation | $21.59 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Boston Scientific Corporation | $20.74 | 2021-2025 | Axonics |
| Janssen Pharmaceuticals, INC | $14.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Aversa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.